Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Valeritas ($VLRX) Expands Market Footprint

|About: Valeritas Holdings, Inc. (VLRX)
Summary

Valeritas signed exclusive distribution deal with TRITECH BioMed.

TRITECH BioMed will have the rights to promote, market and sell the V-Go to diabetes clinics and patients in Israel.

Over 600,000 patients with diabetes in Israel.

The deal, which did not provide a financial disclosure, helps increase the footprint of VLRX as they look to expand into international markets.

The V-Go product is a wearable insulin device for patients with Type-2 diabetes. It is worn like a patch and delivers a preset basal rate of insulin over the course of 24 hours.  VLRX is down to .33 in early morning trading.

Valeritas Holdings, Inc. is a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with diabetes. It offers products under the V-Go brand. V-Go Disposable Insulin Delivery Device, is used by patients with type 2 diabetes to maintain target blood glucose goals. The firm's single-use disposable V-Go device includes V-Go PreFill and V-Go Link. The company was founded by Leisa Swanson and Robert R. Gonnelli on May 9, 2014 and is headquartered in Bridgewater, NJ

Disclosure: I am/we are long VLRX.